

Haematologica
HAEMATOL/2020/267831
Version 3

Standardization of flow cytometric minimal residual disease
assessment in international clinical trials - a feasibility study from the
European Myeloma Network

Davine Hofste op Bruinink, Stefania Oliva, Lucie Rihova, Alexander
Schmitz, Milena Gilestro, Jeroen te Marvelde, Romana Kralova, Helle
Høholt, Annemiek Broijl, Hans Erik Johnsen, Roman Hajek, Mario
Boccardo, Pieter Sonneveld, Paola Omedè, Vincent H.J. van der
Velden, and European Myeloma Network
(Collaborative Groups: European Myeloma Network)

Disclosures: Funding: This work was supported by grants from the European Myeloma Network and the Ministry of Health of the Czech Republic (grant number 17-30089A). Conflict of interest: The authors declare the following potential conflicts of interest: SO, Honoraria: Celgene, Janssen, Amgen, Adaptive Biotechnologies. AB, Honoraria/Advisory board: Celgene, Janssen, Amgen, Takeda. PS: Research support: Janssen, Celgene, Amgen. Advisory board: Janssen, Celgene, Amgen. DHoB, LR, AS, MG, JtM, RK, HH, HEJ, RH, MB, PO, VvdV: no conflicts of interest.

Contributions: Conceptualization: DHoB, VvdV; Investigation: DHoB, SO, LR, AS, MG, JtM, RK, HH, PO, VvdV; Resources: DHoB, SO, AB; Data curation: DHoB, SO, LR, AS, PO, VvdV; Writing – original draft preparation: DHoB; Writing – review and editing: SO, LR, AS, MG, JtM, RK, HH, AB, RH, MB, PS, PO, VvdV; Visualisation: DHoB; Supervision: HEJ, RH, MB, PS, PO, VvdV; Project administration: DHoB; Funding acquisition: RH, PS.